ClinicalTrials.gg
RecruitingNCT06281977SEDATEUpdated Jul 7, 2026

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

A Phase 3 interventional study of Dexmedetomidine and Normal saline in Ventricular Tachycardia, Ventricular Arrhythmias and Ventricular Fibrillation, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Ottawa Heart Institute Research Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Tachycardia, Ventricular with a site in United States — 34 open to participants now, 40 under way, 2 of them phase 3. Tachycardia, Ventricular · United States.

Planned enrollment
27th of 107
192 · median 60
Started
2024
with 6 others
Phase 3
13 of 154
2 open now
Primary completion
2027-05
later than 15 of 39 live
Registered
136th of 154
by date

Among the 154 studies in Tachycardia, Ventricular with a site in United States, this one is the 27th largest by planned enrollment of the 107 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 in phase 3, reaches primary completion later than 15 of the 39 other live ones, and was the 136th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

34 of the 154 studies in Tachycardia, Ventricular with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Tachycardia, Ventricular with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.

Read the detailed description

Electrical storm (ES), defined as three or more sustained or treated ventricular arrhythmias in a 24-hour period, is a life-threatening condition that is associated with significant short- and long-term mortality. Autonomic dysfunction from increased sympathetic tone and the catecholamine surge from defibrillator shocks can precipitate recurrent ventricular arrhythmias and exacerbate ES. Although the mainstay of treatment are anti-arrhythmic drugs, sedative agents and procedures are commonly used to decrease sympathetic tone. These therapies have been studied in refractory ES but the benefit of early sedation remains unclear.

Alpha-2 agonism with dexmedetomidine can provide conscious sedation without the need for mechanical ventilation. Dexmedetomidine has been found to reduce ventricular arrhythmia events in non-ES patients in the intensive care unit and in the peri-operative period. Its antiarrhythmic properties are thought to be due to catecholamine suppression, prolonging electrical refractory periods, and increasing vagal tone. Its rapid onset and favorable safety profile render alpha-2 agonism with dexmedetomidine a potentially valuable therapy for patients with ES.

This study is a multi-centre, double-blinded, placebo-controlled, randomized trial that will evaluate the effectiveness of dexmedetomidine in the acute treatment of ES. Consecutive patients admitted to an intensive care unit will be randomized to receive dexmedetomidine or placebo at the time of presentation. The study drug will be titrated to a maintenance dose and continued for 48 hours before being weaned.

03

Conditions studied

  • Ventricular Tachycardia
  • Ventricular Arrhythmias
  • Ventricular Fibrillation
  • Recurrent Ventricular Tachycardia

Keywords

  • Electrical Storm
  • Dexmedetomidine
  • Ventricular Electrical Storm
  • Precedex
  • Recurrent Ventricular Arrhythmias
  • Recurrent Ventricular Tachycardia
  • Sedation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.

Exclusion criteria

Exclusion Criteria:

  • shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
  • SCAI class D or E cardiogenic shock
  • Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.
  • ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.
  • Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.
  • Pregnancy
  • Known dexmedetomidine allergy or intolerance
  • Inability to obtain consent from patient or substitute decision maker.
  • Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
192 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine

    Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo

    Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.

    Drug: Normal saline

Interventions

  • Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.

    Also known as: Precedex

  • DrugNormal saline

    Programed as dexmedetomidine on infusion pump.

06

What researchers measure

Primary outcomes

  1. The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

Secondary outcomes

  1. All-cause in-hospital death

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  2. Ventricular arrhythmia requiring treatment after study drug initiation

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  3. Resuscitated cardiac arrest after study drug initiation

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  4. Renal failure requiring new initiation of renal replacement therapy after study drug initiation

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  5. Intubation following study drug initiation

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  6. Length of stay in the intensive care unit

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  7. Length of stay in hospital

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  8. Need for mechanical circulatory support device after study drug initiation

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  9. Ventricular Arrhythmia requiring treatment only during active study drug treatment

    Defined as anytime the participant is receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

  10. Pacing or treatment with isoproterenol for treatment of bradyarrhythmia after study drug initiation.

    Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo

    Time frame: Duration of index hospitalization - an average of 2 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Motazedian P, Di Santo P, Prosperi-Porta G, Nelson D, Morgan B, Ratelle C, Feagan H, Koopman Z, Jung R, Mathieu ME, Knoll W, Parlow S, Abdel-Razek O, Mathew R, Wells GA, Chiu MH, Ballantyne B, Hibbert B, Ramirez FD. Study evaluating dexmedetomidine in the acute treatment of electrical storm (SEDATE): Rationale and design. Am Heart J. 2026 May;295:107358. doi: 10.1016/j.ahj.2026.107358. Epub 2026 Jan 25. PubMed 41592634 ↗

Individual participant data

Plan to share: Yes — The study data, protocol, SAP, ICF, and CSR will be made available at study completion/publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Study completion

Access criteria: The above will be made publicly available

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 28, 2024
StartActual
May 8, 2024
Primary completionEst.
May 8, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06281977
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
May 8, 2024
Primary completion
May 8, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

F. Daniel Ramirez, MD MSc
Contact
dramirez@ottawaheart.ca
613-696-7402
Benjamin Hibbert, MD PhD
Contact
hibbert.benjamin@mayo.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion